Cortexin

Cortexin is a lyophilized complex of low-molecular-weight polypeptides (1,000–10,000 Da, predominantly acidic and neutral fractions) extracted from the cerebral cortex of cattle. Radiolabeled studies in mice confirmed that the peptides cross the blood-brain barrier, with brain concentrations reaching 6–8% of whole-blood levels following intramuscular injection.

The preparation acts through several complementary pathways. In vitro receptor-binding assays at 10 µg/ml demonstrated binding affinity at AMPA receptors (80.1%), kainate receptors (73.5%), metabotropic glutamate receptor 1 (mGluR1, 49.0%), GABA-A1 (44.0%), and mGluR5 (39.7%), consistent with attenuation of glutamatergic excitotoxicity and augmentation of GABAergic inhibitory tone. Identified protein binding partners in neural tissue include the cytoskeletal protein β5-tubulin, the energy-metabolism enzyme creatine kinase B, and the signaling scaffold protein 14-3-3 α/β, linking the preparation to neuroplasticity, cellular energy homeostasis, and signal transduction networks.

• Anti-apoptotic effect: Cortexin selectively inhibits caspase-8 in brain tissue in a tissue-specific manner, attenuating the extrinsic apoptotic cascade without broad systemic protease inhibition. • Antioxidant activity: In rodent ischemia models it restores superoxide dismutase activity, reduces malondialdehyde concentration, and elevates glutathione levels. • Epigenetic modulation: Cortexin peptide derivatives bind histone H1.3, potentially altering chromatin conformation and influencing gene expression in neurons, though the downstream functional significance in humans remains uncharacterized.

The evidence base for Cortexin is derived almost entirely from Russian and former-Soviet research. A 2021 international systematic review and meta-analysis of animal-derived nootropics (PMC9616232) rated the available controlled evidence for Cortexin as "very low" quality, identifying only one qualifying randomized trial with 80 participants; MoCA scores above 26 increased from baseline by 27.5% in the Cortexin group at 12-month follow-up. The same review found 19 eligible trials for Cerebrolysin by comparison, underscoring Cortexin's thinner independently verified evidence base.

Larger Russian multicenter trials exist, though their methodological transparency has not been independently validated. A multicenter double-blind placebo-controlled trial in 272 patients with acute ischemic stroke (PMID 24874316) tested 10 mg three times daily over two sequential 10-day courses and concluded that the two-course regimen produced the most favorable clinical outcomes. A multicenter RCT in 189 patients with chronic cerebral ischemia stages I–II (PMID 30335070) found dose-dependent improvements in neurological symptom severity, asthenia, and sleep disturbance; antioxidant effects were independent of dose between the 10 mg and 20 mg arms. An open multicenter study in 500 patients with stage II brain ischemia across 70 Russian sites (PMID 25403301) found regression of focal neurological symptoms and improvements on the MMSE, Five Words Test, Schulte attention test, Hamilton Anxiety Scale, and Geriatric Depression Scale.

In pediatrics, a prospective multicenter trial (n=635, ages 3–7) across ADHD, speech delay, perinatal CNS lesion, and asthenic-neurotic subgroups found statistically significant improvements (p<0.001) in attention, visual memory, and thinking after ten daily IM injections; gains were greatest in the ADHD subgroup and among younger children.

Preclinically, 224 male rats in acute MCAO and chronic carotid-stenosis models showed approximately 45% necrosis reduction, improved Morris water maze performance, and restored antioxidant markers at 1–3 mg/kg/day Cortexin (PMC8279368). Cortexin is not approved by the FDA or EMA, and no independent Cochrane review covering this compound currently exists.

Typical dosage: 10 mg (daily for cycles).

Cortexin is supplied as a lyophilized powder in 5 mg or 10 mg vials for intramuscular injection only. No oral dosage form exists. All doses below refer to the IM route.

• Adults — general neurology and chronic conditions: 10 mg once daily for 10 consecutive days. Treatment courses are separated by intervals of 3 to 6 months based on clinical response. • Adults — acute ischemic stroke (protocol used in the 272-patient double-blind trial, PMID 24874316): 10 mg intramuscularly twice daily (morning and early afternoon) for 10 days, followed by a 10-day rest, then a second identical 10-day course. • Chronic cerebral ischemia (multicenter RCT, PMID 30335070): 10 mg or 20 mg once daily for 10 days; course repeated after 6 months. The 10 mg and 20 mg arms showed comparable cognitive outcomes; neurological and sleep benefits were dose-dependent. • Children weighing less than 20 kg: 0.5 mg/kg/day IM for 10 days. • Children weighing 20 kg or more: 10 mg/day IM for 10 days.

The manufacturer (Geropharm) advises against using lidocaine as a reconstitution solvent in children owing to elevated adverse-reaction risk; isotonic saline or water for injection is the preferred diluent. An experimental rectal suppository formulation at 16 mg/kg was studied in rodent developmental models but is not an approved clinical dosage form.

This information is provided for educational reference only and does not constitute medical advice. Cortexin is not approved by the FDA or EMA; dosing decisions require evaluation by a licensed physician familiar with the patient's individual clinical circumstances.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

No peer-reviewed studies have specifically evaluated Cortexin combined with other nootropic or neuroprotective agents to enhance cognitive outcomes. In Russian clinical practice it is administered as an adjunct to standard-of-care medications — anticoagulants, antihypertensives, and antiplatelet agents in ischemic stroke — without published pharmacokinetic interaction data. An open-label study in post-stroke epilepsy patients (PMID 20873481) reported tolerability when Cortexin 10 mg IM for 15 days was added to existing antiepileptic drug regimens, though no pharmacokinetic or efficacy data specific to the combination were provided.

Community nootropic users report stacking Cortexin with Cerebrolysin, piracetam, or other polypeptide preparations, citing potentially complementary mechanisms: Cortexin's glutamate-receptor modulation alongside Cerebrolysin's neurotrophic peptide profile. This rationale is entirely anecdotal; no clinical trial has evaluated any such combination, and the safety and efficacy of these informal stacks are unknown.

Cortexin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Generally well-tolerated

Russian pharmacovigilance data classify adverse reactions to Cortexin as "very rare" (frequency less than 1 in 10,000). Reported events in prescribing information include: anaphylactic shock, drug hypersensitivity, angioedema, urticaria, rash, pruritus, allergic dermatitis, psychomotor agitation, ataxia, headache, dizziness, drowsiness, tachycardia, arrhythmia, anxiety, insomnia, injection-site hyperemia, fever, asthenia, chills, and elevated blood pressure. No adverse effects were detected in the 635-patient pediatric multicenter trial, which classified tolerability as excellent. The single qualifying trial in the 2021 systematic review (n=80) reported zero adverse events or discontinuations.

Contraindications per Russian prescribing information are limited to individual hypersensitivity to any component of the preparation. Use in pregnancy is contraindicated on precautionary grounds owing to the absence of controlled human data; use during breastfeeding is similarly unstudied and not recommended.

Lidocaine used as a reconstitution solvent carries additional allergenic risk and is specifically discouraged in children by the manufacturer; saline or sterile water for injection is preferred in all pediatric applications.

As a bovine-derived biological preparation, theoretical concerns about batch-to-batch variability in peptide composition and prion (transmissible spongiform encephalopathy) contamination exist as a class-level risk; no such adverse events have been reported in the published literature. No formal drug interaction studies have been conducted. The preparation holds no FDA, EMA, or MHRA marketing authorization, meaning the quality-control and post-market surveillance requirements standard for approved Western pharmaceuticals do not apply to Cortexin obtained through informal importation channels.